Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial

Tosi Mwakyandile, Grace Shayo, Sabina Mugusi, Bruno Sunguya, Philip Sasi, Candida Moshiro, Ferdinand Mugusi, Eligius Lyamuya, Tosi Mwakyandile, Grace Shayo, Sabina Mugusi, Bruno Sunguya, Philip Sasi, Candida Moshiro, Ferdinand Mugusi, Eligius Lyamuya

Abstract

Introduction: An increase in cardiovascular disease (CVD) among people living with HIV infection is linked to platelet and immune activation, a phenomenon unabolished by antiretroviral (ARV) drugs alone. In small studies, aspirin (acetylsalicylic acid [ASA]) has been shown to control immune activation, increase CD4+ count, halt HIV disease progression and reduce HIV viral load (HVL). We present a protocol for a larger ongoing randomised placebo controlled trial on the effect of an addition of ASA to ARV drugs on HIV disease progression.

Methods and analysis: A single-centre phase IIA double-blind, parallel-group randomised controlled trial intends to recruit 454 consenting ARV drug-naïve, HIV-infected adults initiating ART. Participants are randomised in blocks of 10 in a 1:1 ratio to receive, in addition to ARV drugs, 75 mg ASA or placebo for 6 months. The primary outcome is the proportion of participants attaining HVL of <50 copies/mL by 8, 12 and 24 weeks. Secondary outcomes include proportions of participants with HVL of >1000 copies/mL at week 24, attaining a >30% rise of CD4 count from baseline value at week 12, experiencing adverse events, with normal levels of biomarkers of platelet and immune activation at weeks 12 and 24 and rates of morbidity and all-cause mortality. Intention-to-treat analysis will be done for all study outcomes.

Ethics and dissemination: Ethical approval has been obtained from institutional and national ethics review committees. Findings will be submitted to peer-reviewed journals and presented in scientific conferences.

Trial registration number: PACTR202003522049711.

Keywords: HIV & AIDS; clinical pharmacology; coronary heart disease; general medicine (see internal medicine); immunology; infectious diseases.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Joint United Nations Program on HIV/AIDS(UNAIDS) . UNAIDS data 2017, 2017.
    1. Baker RK, Moorman AC. Mortality in the highly active antiretroviral therapy era; changing causes of death and diseases in the HIV outpatient study. J Acquir Immune Defic Syndr 2006:4327–34. 10.1097/01.qai.0000233310.90484.16
    1. Antiretroviral Therapy Cohort Collaboration . Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293–9. 10.1016/S0140-6736(08)61113-7
    1. Rodger AJ, Lodwick R, Schechter M, et al. . Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the smart and ESPRIT trials compared with the general population. AIDS 2013;27:973–9. 10.1097/QAD.0b013e32835cae9c
    1. Marin B, Thiébaut R, Bucher HC, et al. . Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009;23:1743–53. 10.1097/QAD.0b013e32832e9b78
    1. , Smith C, Sabin CA, et al. , Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group . Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537–48. 10.1097/QAD.0b013e32833a0918
    1. Sackoff JE, Hanna DB, Pfeiffer MR, et al. . Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: new York City. Ann Intern Med 2006;145:397–406. 10.7326/0003-4819-145-6-200609190-00003
    1. Antiretroviral Therapy Cohort Collaboration . Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387–96. 10.1086/652283
    1. Islam FM, Wu J, Jansson J, et al. . Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453–68. 10.1111/j.1468-1293.2012.00996.x
    1. Bavinger C, Bendavid E, Niehaus K, et al. . Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 2013;8:e59551. 10.1371/journal.pone.0059551
    1. Hemkens LG, Bucher HC. Novel therapeutic concepts HIV infection and cardiovascular disease. Eur Heart J 2014;35:1373–81.
    1. Lichtenstein KA, Armon C, Buchacz K, et al. . Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010;51:435–47. 10.1086/655144
    1. Lang S, Mary-Krause M, Simon A, et al. . HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012;55:600–7. 10.1093/cid/cis489
    1. McKibben RA, Margolick JB, Grinspoon S, et al. . Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015;211:1219–28. 10.1093/infdis/jiu594
    1. Burdo TH, Lo J, Abbara S, et al. . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011;204:1227–36. 10.1093/infdis/jir520
    1. Subramanian S, Tawakol A, Burdo TH, et al. . Arterial inflammation in patients with HIV. JAMA 2012;308:379–86. 10.1001/jama.2012.6698
    1. Kelesidis T, Kendall MA, Yang OO, et al. . Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012;206:1558–67. 10.1093/infdis/jis545
    1. Longenecker CT, Funderburg NT, Jiang Y, et al. . Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013;14:385–90. 10.1111/hiv.12013
    1. O'Brien M, Montenont E, Hu L, et al. . Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013;63:280–8. 10.1097/QAI.0b013e31828a292c
    1. Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta 2012;413:1338–49. 10.1016/j.cca.2011.11.006
    1. Arneth BM. Activation of CD4 and CD8 T cell receptors and regulatory T cells in response to human proteins. PeerJ 2018;6:e4462. 10.7717/peerj.4462
    1. Poesen R, Ramezani A, Claes K, et al. . Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD. Clin J Am Soc Nephrol 2015;10:1525–33. 10.2215/CJN.03100315
    1. Reiner AP, Lange EM, Jenny NS, et al. . Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 2013;33:1–18. 10.1161/ATVBAHA.112.300421
    1. Longenecker CT, Jiang Y, Orringer CE, et al. . Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014;28:969–77. 10.1097/QAD.0000000000000158
    1. Blann AD, Nadar SK, Lip GYH,. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24:2166–79. 10.1016/j.ehj.2003.08.021
    1. Scialla JJ, Plantinga LC, Kao WHL, et al. . Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients. Am J Nephrol 2011;33:224–30. 10.1159/000324517
    1. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103:491–5. 10.1161/01.CIR.103.4.491
    1. Hunt PW, Brenchley J, Sinclair E, et al. . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126–33. 10.1086/524143
    1. Hunt PW, Martin JN, Sinclair E, et al. . T cell activation is associated with lower CD4 + T cell gains in human immunodeficiency virus–infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534–43 10.1086/374786
    1. Nkambule BB, Mxinwa V, Mkandla Z, et al. . Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis. BMC Med 2020;18:357. 10.1186/s12916-020-01801-9
    1. Hattab S, Guiguet M, Carcelain G, et al. . Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. HIV Med 2015;16:553–62. 10.1111/hiv.12257
    1. Malherbe G, Steel HC, Cassol S. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediators Inflamm 2014;2014:1–7. 10.1155/2014/198413
    1. Wada NI, Jacobson LP, Margolick JB, et al. . The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015;29:463–71. 10.1097/QAD.0000000000000545
    1. O'Halloran JA, Dunne E, Gurwith M, et al. . The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Med 2015;16:608–19. 10.1111/hiv.12270
    1. Wolf K, Tsakiris DA, Weber R, et al. . Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185:456–62. 10.1086/338572
    1. Mesquita EC, Hottz ED, Amancio RT, et al. . Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. Sci Rep 2018;8:1–10. 10.1038/s41598-018-33403-0
    1. Falcinelli E, Francisci D, Belfiori B, et al. . In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost 2013;110:349–57. 10.1160/TH12-07-0504
    1. Baum PD, Sullam PM, Stoddart CA, et al. . Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011;25:2243–8. 10.1097/QAD.0b013e32834d3cc3
    1. Gresele P, Falcinelli E, Momi S, et al. . Highly active antiretroviral therapy-related mechanisms of endothelial and platelet function alterations. Rev Cardiovasc Med 2014;15 Suppl 1:S9–20.
    1. Falcinelli E, Francisci D, Schiaroli E. Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. Int J Cardiol 2018. 10.1016/j.ijcard.2018.04.052
    1. O'Brien MP, Hunt PW, Kitch DW, et al. . A randomized placebo controlled trial of aspirin effects on immune activation in chronically human immunodeficiency virus-infected adults on virologically suppressive antiretroviral therapy. Open Forum Infect Dis 2017;4:1–10. 10.1093/ofid/ofw278
    1. Stanczuk GA, Thomsen M, Soerensen AM, et al. . Acetyl salicylic acid (aspirin), micronutrients and chloroquine in the management of the acquired immunodeficiency syndrome (AIDS). Cent Afr J Med 2002;48:42–9. 10.4314/cajm.v48i3-4.51695
    1. Sibanda EN, Stanzuk GA, Thomsen M. Acetyl salicylic acid (ASPIRIN) increases the CD4+ Tlymphocytes and suppresses TNF-a in HIV-I infected patients: results of a 12 month, three-arm, placebo-controlled pilot study. AIDS vaccines Relat Top 2004;1:179–90.
    1. Durosinmi MA, Armistead H, Akinola NO, et al. . Selenium and aspirin in people living with HIV and AIDS in Nigeria. Niger Postgrad Med J 2008;15:215–8.
    1. Cantudo-Cuenca MR, Jiménez-Galán R, Almeida-Gonzalez CV, et al. . Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J Manag Care Spec Pharm 2014;20:844–50. 10.18553/jmcp.2014.20.8.844
    1. Horberg MA, Silverberg MJ, Hurley LB, et al. . Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008;47:384–90. 10.1097/QAI.0b013e318160d53e
    1. Palepu A, Tyndall MW, Joy R, et al. . Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006;84:188–94. 10.1016/j.drugalcdep.2006.02.003
    1. United Republic of Tanzania . World population policies 2019, 2020.
    1. Drake BJ, Sarah D, Tina C, et al. . CD4 count recovery after antiretroviral therapy initiation in patients infected with the human immunodeficiency virus. Am J Med Sci [Internet] 2016.
    1. Sangeda RZ, Mosha F, Prosperi M, et al. . Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health 2014;14:1–11. 10.1186/1471-2458-14-1035
    1. Soomro H, Aleem S, Hussain M, et al. . Frequency and predictors of non-compliance to aspirin therapy in post myocardial infarction patients. Glob J Health Sci 2017;9:217–23. 10.5539/gjhs.v9n1p217
    1. Walmsley SL, Antela A, Clumeck N, et al. . Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369:1807–18. 10.1056/NEJMoa1215541
    1. Huang ES, Strate LL, Ho WW, et al. . Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011;124:426–3310.1016/j.amjmed.2010.12.022
    1. Misra S. Randomized double blind placebo control studies, the “gold standard” in intervention based studies. Indian J Sex Transm Dis 2012;33:131–4. 10.4103/0253-7184.102130

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir